The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings
- PMID: 9872654
The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings
Abstract
Immunophenotypic studies have a limited role in the diagnosis of chronic myelogenous leukemia (CML) but are increasingly being used in CML blast transformation (BT). Determination of the cell lineage of CML blasts is clinically important because patients with lymphoid blast transformation have a better response to chemotherapy and longer survival than those with other lineages. We studied the morphologic, cytochemical, immunophenotypic, cytogenetic, and molecular features of 20 patients with Philadelphia chromosome-positive CML and more than 10% blast cells in peripheral blood or bone marrow. The blasts were morphologically heterogeneous. CD33 was expressed in 19 cases (95%), followed by CD13 (85%), CD11c (80%), CD36 (60%), CD117 (40%), and CD15 (30%). Seven cases (35%) had a precursor-B lymphoid immunophenotype, and 13 (65%) had a predominantly myeloid immunophenotype. Of the former group, of which only one had a pure lymphoid phenotype, terminal deoxynucleotidyl transferase (TdT) and CD19 were expressed in 100%, CD10 in 85.7%, and CD20 in 14.3%. Of the latter group, all 13 expressed from 3 to 6 myeloid antigens, with 46.2% myeloperoxidase positive and 69.2% CD61 positive. No cases were interpreted as T lineage, but the T-cell antigens CD3, CD4, CD5, and CD7 were expressed in 5.0, 40.0, 5.3. and 30.0% of all cases, respectively. In most cases, the immunophenotype of the CML blasts could not be predicted from their morphologic features. Polymerase chain reaction showed that 80.0% of the lymphoid group and 37.5% of the myeloid group had immunoglobulin heavy-chain gene rearrangements. The frequent lineage infidelity of the blast cells in CML BT seems to be related to the stem cell origin of this disorder. Such lineage infidelity, however, makes classification of many cases difficult and the significance of and criteria for biphenotypic blast crisis of CML is yet to be determined.
Similar articles
-
Immunophenotypic characteristics of the blast crisis in chronic myeloid leukemia.Rev Invest Clin. 1997 Jan-Feb;49(1):31-6. Rev Invest Clin. 1997. PMID: 9229753 Review.
-
T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia.Exp Hematol. 1993 Jun;21(6):743-8. Exp Hematol. 1993. PMID: 7684698
-
CD56+CD7+ stem cell leukemia/lymphoma with D2-Jdelta1 rearrangement.Intern Med. 1999 Jul;38(7):547-55. Intern Med. 1999. PMID: 10435360
-
Blast crisis of chronic myelogenous leukemia exhibiting immunophenotypic features of a myeloid/natural killer cell precursor.Int J Hematol. 1999 Feb;69(2):89-91. Int J Hematol. 1999. PMID: 10071456
-
Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis.Haematologica. 1997 Sep-Oct;82(5):596-9. Haematologica. 1997. PMID: 9407730 Review.
Cited by
-
South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook.Afr J Lab Med. 2022 May 31;11(1):1578. doi: 10.4102/ajlm.v11i1.1578. eCollection 2022. Afr J Lab Med. 2022. PMID: 35747555 Free PMC article.
-
Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations.Blood Adv. 2021 Dec 28;5(24):5612-5616. doi: 10.1182/bloodadvances.2021005308. Blood Adv. 2021. PMID: 34581783 Free PMC article.
-
B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature.AJSP Rev Rep. 2019 Sep-Oct;24(5):191-195. AJSP Rev Rep. 2019. PMID: 32656356 Free PMC article.
-
Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.Int J Hematol. 2005 May;81(4):307-9. doi: 10.1532/IJH97.04188. Int J Hematol. 2005. PMID: 15914360
-
NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature.Mediterr J Hematol Infect Dis. 2020 Nov 1;12(1):e2020083. doi: 10.4084/MJHID.2020.083. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 33194157 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous